Intra-cellular Therapies, Inc.

ITCI

Pharmaceutical Preparations

Mkt Cap

$6.357B

PE

-57.34

Debt

Cash

$141.6M

EV

FCF

Market Cap

$6.357B

P/E Ratio

-57.34

Debt

Cash

$141.6M

EV

FCF

Charts data: {"Earnings":[{"time":"2014-12-30","value":-30691460},{"time":"2015-12-30","value":-104793141},{"time":"2016-12-30","value":-116426268},{"time":"2017-12-30","value":-97773414},{"time":"2018-12-30","value":-155127411},{"time":"2019-12-30","value":-147722178},{"time":"2020-12-30","value":-227005663},{"time":"2021-12-30","value":-284125666},{"time":"2022-12-30","value":-256256000},{"time":"2023-12-30","value":-139674000}],"Sales":[{"time":"2014-12-30","value":577301},{"time":"2015-12-30","value":91364},{"time":"2016-12-30","value":330702},{"time":"2017-12-30","value":245837},{"time":"2019-12-30","value":60613},{"time":"2020-12-30","value":22812979},{"time":"2021-12-30","value":83803017},{"time":"2022-12-30","value":250314000},{"time":"2023-12-30","value":464370000}],"Net Margins":[{"time":"2014-12-30","value":-53.16370489571298},{"time":"2015-12-30","value":-1146.985037870496},{"time":"2016-12-30","value":-352.05794945298186},{"time":"2017-12-30","value":-397.71642999223064},{"time":"2019-12-30","value":-2437.1368848266875},{"time":"2020-12-30","value":-9.95072423465607},{"time":"2021-12-30","value":-3.3903990115296208},{"time":"2022-12-30","value":-1.0237381848398412},{"time":"2023-12-30","value":-0.3007817042444602}],"Assets":[{"time":"2014-12-30","value":131111769},{"time":"2015-12-30","value":484103528},{"time":"2016-12-30","value":388903495},{"time":"2017-12-30","value":471486699},{"time":"2018-12-30","value":357206498},{"time":"2019-12-30","value":251186476},{"time":"2020-12-30","value":717313674},{"time":"2021-12-30","value":489922096},{"time":"2022-12-30","value":754780000},{"time":"2023-12-30","value":728295000}],"Stockholders Equity":[{"time":"2014-12-30","value":120554705},{"time":"2015-12-30","value":476242911},{"time":"2016-12-30","value":375502539},{"time":"2017-12-30","value":454436961},{"time":"2018-12-30","value":317714881},{"time":"2019-12-30","value":195007271},{"time":"2020-12-30","value":656860104},{"time":"2021-12-30","value":417890675},{"time":"2022-12-30","value":656070000},{"time":"2023-12-30","value":591424000}],"ROE":[{"time":"2014-12-30","value":-0.25458533534630606},{"time":"2015-12-30","value":-0.2200413666629885},{"time":"2016-12-30","value":-0.3100545426671536},{"time":"2017-12-30","value":-0.21515286473364123},{"time":"2018-12-30","value":-0.48825982123261014},{"time":"2019-12-30","value":-0.7575213849333854},{"time":"2020-12-30","value":-0.3455921003842852},{"time":"2021-12-30","value":-0.6799042979362964},{"time":"2022-12-30","value":-0.39059246726721236},{"time":"2023-12-30","value":-0.23616559355048156}],"ROA":[{"time":"2014-12-30","value":-0.234074028853962},{"time":"2015-12-30","value":-0.21646514627342273},{"time":"2016-12-30","value":-0.29663038898634736},{"time":"2017-12-30","value":-0.20962259425265356},{"time":"2018-12-30","value":-0.43427488544735265},{"time":"2019-12-30","value":-0.5880912872076759},{"time":"2020-12-30","value":-0.3164475434215687},{"time":"2021-12-30","value":-0.5799290077335071},{"time":"2022-12-30","value":-0.3395029015077241},{"time":"2023-12-30","value":-0.19090890367227567}]}

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19
10-Q
3/31/19
10-K
12/31/18
10-Q
9/30/18
10-Q
6/30/18
10-Q
3/31/18
10-K
12/31/17

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Over time the ROA has been increasing indicating a higher marginal ROA with respect to the calculated one, giving a good sign for continued growth.

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-110K%	-35K%	-40K%	-	-240K%	-1K%	-340%	-100%	-30%	-22%
ROA	-22%	-30%	-21%	-43%	-59%	-32%	-58%	-34%	-19%	-15%
ROE	-22%	-31%	-22%	-49%	-76%	-35%	-68%	-39%	-24%	-18%

What is the average Net Margin?

The average Net Margin over the past 5 years is -49.04K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +48.83K%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -40.82%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +4.85%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -48.3%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +5.79%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-	-	-	-	-	-	-	-
Debt Equity	-	-	-	-	-	-	-	-	-	-
MIN
Graham Stability	-	-	-	-	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2016	12-2018	12-2020	12-2022	Trend
Revenue	180%	-	170%	86%	560%
Net Income	-	-	-	-	-
Stockholders Equity	6.7%	13%	-3.4%	-9.9%	-14%
FCF	-	-	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +563.21%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -2.08%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +13.23%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -13.88%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +0.98%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.